DUBLIN (BUSINESS WIRE) The "Incontinence Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.The report provides comprehensive information about the Incontinence Devices p.
Allterum Therapeutics completes Series Seed offering, builds team with addition of Philip Breitfeld as Chief Medical Officer
News provided by
Share this article
Share this article
HOUSTON, Dec. 17, 2020 /PRNewswire/ Allterum Therapeutics, Inc. completed its $1.8 million Series Seed offering to members of the FanninDirect
SM investor group. Allterum is developing a novel immunotherapy for treatment of IL7R-expressing cancers, including difficult to treat cases of pediatric acute lymphoblastic leukemia (ALL), a program which has received both Orphan Drug and Rare Pediatric Disease Designations from FDA. The company will use the proceeds for its pre-clinical antibody manufacturing and toxicology work and to continue to build the management team.